共 50 条
- [1] Strategic inhibition of adenosine A2A receptor (A2AR) by CPI-444 improves CD8+ :Treg ratios and enhances T-cell killing of a HER-2/neu expressing murine tumorCANCER RESEARCH, 2017, 77Scott, Blake A.Armstrong, ToddWillingham, StephenMcCaffery, IanJaffee, Elizabeth M.
- [2] CPI-444, an oral adenosine A2a receptor (A2aR) antagonist, demonstrates clinical activity in patients with advanced solid tumorsCANCER RESEARCH, 2017, 77Emens, LeishaPowderly, JohnFong, LawrenceBrody, JoshuaForde, PatrickHellmann, MatthewHughes, BrettKummar, ShivaaniLoi, ShereneLuke, JasonMahadevan, DarukaMarkman, BenjaminMcCaffery, IanMiller, RichardLaport, Ginna
- [3] Clinical activity of adenosine 2A receptor (A2AR) inhibitor CPI-444 is associated with tumor expression of adenosine pathway genes and tumor immune modulationJOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5Hotson, AndrewPowderly, JohnEmens, LeishaForde, PatrickHellman, MatthewFong, LawrenceMarkman, BenHughes, BrettGoldman, JonathanSznol, MarioMahadevan, DarukaKummar, ShivaaniBrody, JoshuaBonomi, PhilipLuke, JasonRiese, MatthewOwonikoko, TaofeekLoi, ShereneWiese, AmyDoebele, RobertLee, JamesGu, ChunyanWillingham, StephenLaport, GinnaMiller, RichardMcCaffery, Ian
- [4] A novel CD73 blocking antibody restores T cell function and augments efficacy of Adenosine 2A Receptor (A2AR) inhibitor CPI-444JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5Piccione, EmilyRudnick, JennyDaine-Matsuoka, BarbaraMikesell, GlenMiller, RichardMcCaffery, Ian
- [5] Monoclonal antibody to HER-2/neu receptor enhances radiosensitivity of esophageal cancer cell lines expressing HER-2/neu oncoproteinINTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2005, 61 (01): : 203 - 211Sato, SKajiyama, YSugano, MIwanuma, YSonoue, HMatsumoto, TSasai, KTsurumaru, M
- [6] Biomarker and clinical activity of CPI-444, a novel small molecule inhibitor of A2A receptor (A2AR), in a Ph1b study in advanced cancersANNALS OF ONCOLOGY, 2016, 27McCaffery, I.Laport, G.Hotson, A.Willingham, S.Patnaik, A.Beeram, M.Miller, R.
- [7] Phase 1/1b multicenter trial of the adenosine A2a receptor antagonist (A2aR) CPI-444 as single agent and in combination with atezolizumab (ATZ) in patients(Pts) with advanced cancersANNALS OF ONCOLOGY, 2016, 27Patnaik, A.Powderly, J.Luke, J.Miller, R.Laport, G.
- [8] Control of tumor growth in normal and transgenic mice by listeria monocytogenes based vaccines for HER-2/neu and the identification of regions of HER-2/neu with cryptic CD8+T cell epitopesFASEB JOURNAL, 2005, 19 (04): : A40 - A40Paterson, YSingh, RJaffee, EMDominiecki, ME
- [9] Immunization with a HER-2/neu helper peptide generates HER-2/neu CD8 T-cell immunity in cancer patientsJOURNAL OF CLINICAL INVESTIGATION, 2001, 107 (04): : 477 - 484Knutson, KLSchiffman, KDisis, ML
- [10] Safety and clinical activity of adenosine A2a receptor (A2aR) antagonist, CPI-444, in anti-PD1/PDL1 treatment-refractory renal cell (RCC) and non-small cell lung cancer (NSCLC) patients.JOURNAL OF CLINICAL ONCOLOGY, 2017, 35Fong, LawrenceForde, Patrick M.Powderly, John D.Goldman, Jonathan WadeNemunaitis, John J.Luke, Jason JohnHellmann, Matthew DavidKummar, ShivaaniDoebele, Robert CharlesMahadevan, DarukaGadgeel, Shirish M.Hughes, Brett Gordon MaxwellMarkman, BenRiese, Matthew JohnBrody, JoshuaEmens, Leisha A.McCaffery, IanMiller, Richard AlanLaport, Ginna